Segment Information (Details)	12 Months Ended
	Dec. 31, 2025 USD ($) segment	Dec. 31, 2024 USD ($)
Segment Information
Number of segments | segment	1
Interest income	$ 699,061	$ 331,849
Net loss	$ (28,854,197)	(24,590,375)
Segment Reporting, Other Segment Item, Composition, Description	Other segment items included in net loss include insurance expense, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses.
Single reportable segment
Segment Information
Program expenses related to clinical-stage product candidates	$ (19,454,384)	(13,817,021)
Program expenses related to preclinical and discovery programs	(504,013)	(884,049)
Program expenses related to clinical manufacturing candidates	(2,493,101)	(2,589,833)
Personnel-related expenses (including stock-based compensation)	(4,857,879)	(6,560,070)
General and administrative professional and consultant fees	(1,649,327)	(1,667,063)
Other segment items	(736,554)	(1,176,892)
Interest income	699,061	331,849
Other non-cash income (expense) items	142,000	1,772,704
Net loss	$ (28,854,197)	$ (24,590,375)